We are live on ! Find out more
TPTX

Turning Point Therapeutics, Inc. Common Stock
TPTX

Delisted

TPTX was delisted on the 16th of August, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Turning Point Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 208 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 208 → 0 (-208)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $3.06B → $0 (-$3.06B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 208

Holders
–
Holders Change
-208
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
208
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$313M
2
BlackRock
BlackRock
New York
-$285M
3
CAM
Cormorant Asset Management
Massachusetts
-$187M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$144M
5
State Street
State Street
Massachusetts
-$124M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
51
Citadel Advisors
Florida
– -$12.5M -165,650 Closed
Bank of New York Mellon
52
Bank of New York Mellon
New York
– -$11.7M -155,302 Closed
FLAM
53
First Light Asset Management
Minnesota
– -$10.6M -140,801 Closed
Hudson Bay Capital Management
54
Hudson Bay Capital Management
Connecticut
– -$10.5M -139,600 Closed
CCM
55
Chicago Capital Management
Illinois
– -$10.2M -135,112 Closed
SBH
56
Segall Bryant & Hamill
Illinois
– -$9.78M -130,011 Closed
E
57
Ergoteles
New York
– -$9.15M -121,650 Closed
GCIA
58
Gabelli & Co Investment Advisers
New York
– -$8.55M -113,650 Closed
HF
59
HRT Financial
New York
– -$8.46M -112,460 Closed
KCM
60
Kennedy Capital Management
Missouri
– -$8.33M -110,748 Closed
Barclays
61
Barclays
United Kingdom
– -$8.28M -110,018 Closed
Swiss National Bank
62
Swiss National Bank
Switzerland
– -$7.89M -104,900 Closed
CCM
63
Crabel Capital Management
California
– -$7.58M -100,658 Closed
Bank of Montreal
64
Bank of Montreal
Ontario, Canada
– -$7.16K -95,222 Closed
BHMP
65
Bardin Hill Management Partners
New York
– -$6.81M -90,508 Closed
SAM
66
Sectoral Asset Management
Quebec, Canada
– -$6.77M -90,000 Closed
Balyasny Asset Management
67
Balyasny Asset Management
Illinois
– -$6.69M -88,943 Closed
N
68
Natixis
France
– -$6.3M -83,623 Closed
Canada Pension Plan Investment Board
69
Canada Pension Plan Investment Board
Ontario, Canada
– -$6.13M -81,500 Closed
UBS Group
70
UBS Group
Switzerland
– -$5.41M -71,942 Closed
CAM
71
Congress Asset Management
Massachusetts
– -$5.28M -70,100 Closed
PCM
72
Prelude Capital Management
New York
– -$5.2M -69,038 Closed
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
– -$5.12M -68,062 Closed
WMSA
74
Weiss Multi-Strategy Advisers
New York
– -$5.02M -66,722 Closed
SG Americas Securities
75
SG Americas Securities
New York
– -$4.71M -62,660 Closed
1 2
3
4 5

TPTX Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2022, worth a combined $0 — down 100% from $3.06B a quarter earlier.

Sellers outnumbered buyers: 208 funds closed out of TPTX and 0 opened new positions — a net loss of 208 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $313M sold.

  • 0 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2022, down from 208 in Q2 2022.
  • Funds reported $0 of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2022 and 208 closed out, a net change of -208 holders.
  • The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $313M sold.

Based on aggregated 13F filings for Q3 2022.